tetano
Editor, Senior Moderator
J Infect Dis. 2014 Jun 27. pii: jiu359. [Epub ahead of print]
Heterologous Prime-boost Vaccination Using an H5N1-AS03-adjuvanted Influenza Vaccine in Infants and Children Under 3 Years of Age.
Nolan T1, Izurieta P2, Lee BW3, Chan PC4, Marshall H5, Booy R6, Drame M7, Vaughn DW8.
Author information
Abstract
BACKGROUND:
Protecting young children from pandemic influenza should also reduce transmission to susceptible adults, including pregnant women. Methods. An open study (www.clinicaltrials.gov NCT01323946) assessed immunogenicity and reactogenicity of a heterologous booster dose of A/turkey/Turkey/1/2005(H5N1)-AS03B in infants and children aged 6 < 36 months, given six months following two-dose primary vaccination with A/Indonesia/05/2005(H5N1)-AS03B. Vaccines contained 1.9 ?g hemagglutinin antigen and AS03B (α-tocopherol and squalene-based oil-in-water emulsion). Hemagglutinin inhibition (HI) responses, microneutralization and anti-neuraminidase antibodies were assessed to 6 months following booster vaccination.
RESULTS:
For each age stratum (defined when first vaccinated 6 < 12, 12 < 24 and 24 < 36 months) and overall (N = 113), European influenza vaccine licensure criteria were fulfilled for responses to A/turkey/Turkey/1/2005(H5N1) 10 days following booster vaccination. Local pain and fever increased with consecutive doses. Anamnestic immune responses were demonstrated for HI, neutralizing and anti- neuraminidase antibodies against vaccine-homologous/heterologous strains. Antibody responses to vaccine-homologous/heterologous strains persisted in all children six months following booster vaccination.
CONCLUSIONS:
Pre-vaccination of young children with a clade-2 strain H5N1-AS03-adjuvanted vaccine followed by heterologous booster vaccination, boosted immune responses to the homologous strain and a related clade, with persistence for at least 6 months. The results support a prime-boost vaccination approach in young children for pandemic preparedness.
? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID:
24973461
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24973461
Heterologous Prime-boost Vaccination Using an H5N1-AS03-adjuvanted Influenza Vaccine in Infants and Children Under 3 Years of Age.
Nolan T1, Izurieta P2, Lee BW3, Chan PC4, Marshall H5, Booy R6, Drame M7, Vaughn DW8.
Author information
Abstract
BACKGROUND:
Protecting young children from pandemic influenza should also reduce transmission to susceptible adults, including pregnant women. Methods. An open study (www.clinicaltrials.gov NCT01323946) assessed immunogenicity and reactogenicity of a heterologous booster dose of A/turkey/Turkey/1/2005(H5N1)-AS03B in infants and children aged 6 < 36 months, given six months following two-dose primary vaccination with A/Indonesia/05/2005(H5N1)-AS03B. Vaccines contained 1.9 ?g hemagglutinin antigen and AS03B (α-tocopherol and squalene-based oil-in-water emulsion). Hemagglutinin inhibition (HI) responses, microneutralization and anti-neuraminidase antibodies were assessed to 6 months following booster vaccination.
RESULTS:
For each age stratum (defined when first vaccinated 6 < 12, 12 < 24 and 24 < 36 months) and overall (N = 113), European influenza vaccine licensure criteria were fulfilled for responses to A/turkey/Turkey/1/2005(H5N1) 10 days following booster vaccination. Local pain and fever increased with consecutive doses. Anamnestic immune responses were demonstrated for HI, neutralizing and anti- neuraminidase antibodies against vaccine-homologous/heterologous strains. Antibody responses to vaccine-homologous/heterologous strains persisted in all children six months following booster vaccination.
CONCLUSIONS:
Pre-vaccination of young children with a clade-2 strain H5N1-AS03-adjuvanted vaccine followed by heterologous booster vaccination, boosted immune responses to the homologous strain and a related clade, with persistence for at least 6 months. The results support a prime-boost vaccination approach in young children for pandemic preparedness.
? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID:
24973461
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24973461